- Company prepares to bring Kuida CBD brand to Spain with receipt of "no objection" letter
from TSXV, subject to complying with all regulatory requirements in
Spain
- As previously announced, Khiron has fulfilled E.U. cosmetic
product regulatory requirements for seven Kuida products
- Expands on previously announced Kuida entry to the UK
- Company further prepares for Kuida to enter the Swiss market,
conditional on TSXV approval, representing a skincare market of
US$540 million in 2018 (Source:
Euromonitor)
- Spain skincare market
estimated at US$1.7 billion in 2019 (Source:
Euromonitor)
TORONTO, Feb. 20, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, announced today its intent to
bring the Company's Kuida® CBD brand to the Spanish market.
This follows receipt of a "no objection" letter from the TSXV
specific to Spain, and is subject
to meeting all regulatory approvals in that country. With the
previously announced fulfillment of E.U. cosmetic notification
regulatory requirements Khiron will prepare to commercialize Kuida
to a combined skincare market of over US$6.0
billion. (Source: Euromonitor)
"As our European operations ramp up, we are able to bring our
unique products, consumer experience and scientific capabilities
from Latin America into one of the
world's fastest growing markets. Entry for our Kuida
brand into Spain, and later
Switzerland, will represent
another milestone in the Company's strategy to serve consumers
across multiple categories and markets," comments Tejinder Virk, President, Khiron Europe.
Kuida, the first consumer brand of Khiron's wellness business
unit, brings the benefits of cannabidiol (CBD) to a comprehensive
portfolio of skin and body care products for women. Kuida was
launched in Colombia in October 2018 through retail,
wholesale and online channels and is now available nationwide and
through e-commerce channels. As the Company expands Kuida
distribution in Europe, an initial soft launch in the UK will
be followed by a strategic marketing and retail campaign. Kuida
will be a featured exhibitor at Cosmoprof Worldwide Bologna 2020,
which attracted over 265,000 visitors in 2019 and is the largest
such event for attendees to learn more about market leading
products and to place orders. For more information on Kuida
visit https://kuidaskincare.com/en/
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Latin America and is fully licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The company delivers best in class regulatory compliance, has the
first approved set of CBD cosmetic products on shelf
in Colombia, and is currently facilitating testing to meet and
surpass all license requirements for commercial cannabis derived
products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-plans-to-expand-kuida-distribution-to-spain-301008377.html
SOURCE Khiron Life Sciences Corp.